

Changes in the Immunization Schedule Recommended by the Japan Pediatric Society, October 27, 2024



- The "perspective of the Japan Pediatrics Society" on PCV has been added.
- Description regarding the "precautions" for rotavirus vaccine has been updated.
- The target period of routine vaccinations for DPT and IPV have been partially corrected in the Vaccination Schedule table.
- The "perspective of the Japan Pediatrics Society" on DPT has been added.
- The URL citation for the Ministry of Health, Labour and Welfare on the precautions for Japanese encephalitis vaccine has been updated.
- A section on the intranasal live attenuated influenza vaccine has been added.
- Influenza vaccination checklist has been changed according to the above update.
- Description regarding COVID-19 vaccine has been updated and COVID-19 vaccine checklist has been newly created.
- Supplemental information has been added to the "Standard vaccination Age and Period" for the HPV vaccines.
- List of COVID-19 vaccines available in Japan has been newly created.
- Minor revisions have also been made to improve clarity.

Vaccination Schedule Recommended by the Japan Pediatric Society October 27, 2024 Japan Pediatric Society



Vaccine	Type	Infant									Early Childhood					School Age										
		Birth	6w	2m	3m	4m	5m	6m	7m	8m	9-11m	12-15m	16-17m	18-23m	2y	3y	4y	5y	6y	7y	8y	9y	≥10y			
Hepatitis B virus (HBV)	Universal			①	②				③		(Footnote 1)															
	Mother-to-child Transmission	①	②					③																		
Rotavirus	Mono-valent			①	②	Footnote 2																				
	Penta-valent			①	②	③	Footnote 3																			
Pneumococcal (PCV15, PCV20)	Inactivated			①	②	③					④							(Footnote 4)								
DPT-IPV-Hib	Inactivated			①	②	③					④						<7.5 yrs							available <15 yrs		
Diphtheria, Pertussis, Tetanus (DPT)	Inactivated																① (Footnote 5)					② 11-12yrs (Footnote 6)				
Diphtheria, Tetanus (DT)	Inactivated																					① 11yrs	12yrs			
Inactivated polio virus (IPV)	Inactivated																① (Footnote 7)									
Haemophilus influenzae type b *If Hib® is used as first	Inactivated			①	②	③					④													(Footnote 8)		
Diphtheria, Pertussis, Tetanus, Polio (DPT-IPV)	Inactivated			①	②	③					④						<7.5 yrs							available <15 yrs		
BCG	Live								①																	
Measles, Rubella (MR)	Live																①					② (Footnote 9)				
Varicella	Live												①		②									(Footnote 10)		
Mumps	Live												①									② (Footnote 11)				
Japanese Encephalitis	Inactivated															① ② ③	<7.5 yrs					④ 9-12yrs				
Influenza, Inactivated	Inactivated																							① ② ≥13yrs		
Influenza, Live attenuated intranasal	Live																							2 yrs - <19 yrs annually (in October, November, etc.) ① intranasal		
COVID-19	mRNA	Eligible age range varies by COVID-19 vaccine products																								
	Inactivated																									
Human papilloma virus (HPV)	9-valent																						(Footnote 12)	Gr.6	Junior High Gr.1 ①② (footnote 13)	Junior High Gr.2 - High School Gr.1 (Footnote 14)
	2, 4-valent																						(Footnote 12)	Gr.6	Junior High Gr.1 ①②③ (footnote 13)	Junior High Gr.2 - High School Gr.1 (Footnote 14)
Vaccine	Type	Birth	6w	2m	3m	4m	5m	6m	7m	8m	9-11m	12-15m	16-17m	18-23m	2y	3y	4y	5y	6y	7y	8y	9y	≥10y			

Recommended age range for routine vaccination
 Period possible for routine vaccination
 Recommended age range for voluntary vaccination
 Period possible for voluntary vaccination
 Not stated in package insert but recommended by the Japan Pediatric Society
 Period for the national health insurance coverage

Vaccination Schedule Recommended by the Japan Pediatric Society October 27, 2024

Standard Period, Perspective of the Japan Pediatric Society, Precautions

Routine Vaccination
 Voluntary Vaccination
 By Health Insurance



Vaccine	Type	Standard Age of Vaccination and Period	Perspective of the Japan Pediatrics Society	Precautions
Hepatitis B Virus (HBV) Universal Vaccine	Inactivated	① 2 mos ② 3 mos ③ 7-8 mos ≥27 days (4 wks) interval between ①-② ≥139 days (20 wks) interval between ①-③	If there is a hepatitis B virus carrier in the family other than the mother, early vaccination is recommended instead of waiting until the child is 2 mos old.	・ (Footnote 1) For vaccination to prevent horizontal transmission in children who were not vaccinated in infancy, vaccination intervals are the same as for universal vaccines.
Hepatitis B Virus (HBV) Vaccines for Prevention of Mother to Child Transmission	Inactivated	① At birth ② 1 mos ③ 6 mos		If a mother is positive for HBs antigen, ・ The child receives vaccine and HB immunoglobulin simultaneously at birth. ・ Vaccine fee is covered by the national health insurance (Excluded from routine vaccination coverage). ・ See in details at "New strategies for the prevention of mother to child transmission of HBV (in Japanese)" on the website of the Japan Pediatric Society. http://www.jpeds.or.jp/modules/activity/index.php?content_id=141
Rotavirus	Live	① Recommended between 8 wks and under 15 wks (Vaccination possible from 6 wks after birth). ・ RV1 vaccine (Rotarix®): For ①-②, a total of 2 doses with an interval of ≥4 wks. ・ RV5 vaccine (RotaTeq®): For ①-②-③, a total of 3 doses with ≥4 wks between doses.	As a general rule, we do not recommend the first dose of vaccination after 15 wks of age because of the increase in risk of intussusception within 7 days of first vaccination.	・ (footnote2) Total 2 doses, ② to be completed within 24 th wks of age. ・ (footnote3) Total 3 doses, ③ to be completed within 32 nd wks of age. ・ Priority is given to completing the series with the same vaccine, because interchangeability of RV1 and RV5 has not been confirmed yet. ・ Re-vaccination after vomiting the vaccine is not approved as routine vaccination Please refer to the "Q&A for Rotavirus Vaccine" published by the Japan Association of Vaccine Industries for more details (in Japanese). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryuu/kenkou/index_00001.html ・ See "Guideline for Vaccination of the Immunocompromised Host 2024(in Japanese)" for details on rotavirus vaccinations in children whose mother received treatment with biological products during pregnancy.

Vaccination Schedule Recommended by the Japan Pediatric Society October 27, 2024

Standard Period, Perspective of the Japan Pediatric Society, Precautions



Routine Vaccination
 Voluntary Vaccination
 By Health Insurance

Vaccine	Type	Standard Age of Vaccination and Period	Perspective of the Japan Pediatrics Society	Precautions
Pneumococcal, Conjugate (PCV)	Inactivated	≥27 days (4 wks) interval between ①-②-③ ≥60 days (2 mos) interval between ③-④ and administered when the child is 1 yr - 1 yr 3 mos	Refer to "Considerations for the routine vaccination of PCV in children(in Japanese)". https://www.jpeds.or.jp/uploads/files/20241029_haienq.pdf	<ul style="list-style-type: none"> · If first dose administered between 7 mos-11 mos: ③ can be administered after an interval of ≥60 days following ② and after 1 yr of age. · If first dose administered between 1 yr-23 mos: ≥60 days interval between ①-② If the first dose administered between 2 yrs and 4 yrs: only ① · (Footnote4) Regarding the schedule of voluntary vaccinations, please refer to the "Vaccination of Children (under 15 yrs) with Voluntary Vaccines (in Japanese)" on the website of the Japan Pediatric Society http://www.jpeds.or.jp/modules/activity/index.php?content_id=316
DPT-IPV-Hib	Inactivated	Intervals for ①-② and ②-③ are 20-56 days (3-8 wks) For ③-④, ≥6 mos interval is necessary (generally, ④ is given by 18 mos after ③)	④ is recommended to be vaccinated as early as possible, at least 6 mos after ③ and beyond the age of 1 yr	DPT-IPV-Hib vaccine is limited to four doses and cannot be used as a booster dose before elementary school
Diphtheria, Pertussis, Tetanus (DPT)	Inactivated	Intervals for ①-② and ②-③ are 20-56 days (3-8 wks) For ③-④, ≥6 mos interval is necessary (generally, ④ is given by 12-18 mos after ③)	④ is recommended to be vaccinated as early as possible, at least 6 mos after ③ and beyond the age of 1 yr	
Diphtheria, Pertussis, Tetanus (DPT) (For the prevention pertussis after entering elementary school)		⑤ ≥5 yrs, <7 yrs, ≥6 mos between ④-⑤ ⑥ 11-12 yrs	(Footnote5) Because of the decline in pertussis antibody titers in children around 10yrs old, it is recommended that the DPT vaccine given as a booster dose at preschool when four doses of DPT, DPT-IPV, or DPT-IPV-Hib vaccine have been administered. (Footnote 6) It is possible to use DPT vaccine instead of DT vaccine to prevent pertussis.	0.5mL per dose

Vaccination Schedule Recommended by the Japan Pediatric Society October 27, 2024

Standard Period, Perspective of the Japan Pediatric Society, Precautions

Routine Vaccination
 Voluntary Vaccination
 By Health Insurance



Vaccine	Type		Perspective of the Japan Pediatrics Society	Precautions
Diphtheria, Tetanus (DT)	Inactivated	①: At 11 yrs until reaching 12 yrs		· According to the Immunization Law, ≥11 yrs, <13 yrs.
Inactivated poliovirus (IPV)	Inactivated	Intervals for ①-② and ②-③ are 20-56 days (3-8 wks) For ③-④, ≥ 6 mos interval is necessary (generally, ④ is given 12-18 mos after ③)	④ is recommended to be vaccinated as early as possible, at least 6 mos after ③ and beyond the age of 1 yr	
Inactivated poliovaccine (IPV) (For the prevention polio after entering elementary school)		⑤ ≥5 yrs, <7 yrs	(Footnote 7) is recommended as a booster dose of inactivated polio vaccine at entering elementary school, before antibody titer against polio decreases	0.5mL per dose
Haemophilus influenzae type b (Hib)	Inactivated	27-56 days (4-8 wks) interval between ①-②-③ 7-13 mos interval between ③-④	④ should be given ≥7 mos after ③, and as soon as possible after the age of 1 year.	<ul style="list-style-type: none"> · If the first dose is administered between 7 mos and 11 mos: ≥27 (20) days interval between ①-②, and the typical interval between ①-② is 27-56 days (4-8 wks). ≥7 mos interval between ②-③, and the typical interval between ②-③ is 7-13 mos. · If the first dose is administered between 1 yr and 4 yrs: only ① (Footnote 8) Vaccine can be administered for children ≥5 yrs if they have risk factor.
Diphtheria, Pertussis, Tetanus, Polio (DPT-IPV)	Inactivated	Intervals for ①-② and ②-③ are 20-56 days (3-8wks) For ③-④, ≥6 mos interval is necessary (generally, ④ is given 12-18 months after ③)		Maximum of four doses is approved for DPT-IPV. Therefore, for booster doses more than 4th doses, DPT and IPV should be used.

Vaccination Schedule Recommended by the Japan Pediatric Society October 27, 2024

Standard Period, Perspective of the Japan Pediatric Society, Precautions

Routine Vaccination
 Voluntary Vaccination
 By Health Insurance



Vaccine	Type	Standard Age of Vaccination and Period	Perspective of the Japan Pediatrics Society	Precautions
BCG	Live	Administered under 12 mos of age, generally administered during the period from 5 mos to <8 mos.	Early vaccination required in areas where incidence of tuberculosis is high.	
Measles, Rubella (MR)	Live	①: 1 yr - <2 yrs ②: ≥5 yrs - <7 yrs (footnote 9) 1 year before entering		· Vaccination possible ≥6mos for post-exposure prophylaxis; however, the vaccine is not counted, regular ① and ② need to be vaccinated.
Varicella	Live	①: 12-15 mos ②: 6-12 mos after ①	(Footnote 10) It is necessary to provide 2 doses of varicella vaccine for children who are not suffered from varicella and unvaccinated.	<ul style="list-style-type: none"> · ①-②: Leave an interval of ≥3 mos as a routine vaccination. · ①-②: Leave an interval of ≥3 mos if ≥3 yrs - <13 yrs (voluntary vaccination) · ①-②: Leave an interval of ≥4 wks if ≥13 yrs (voluntary vaccination)
Mumps	Live	①: ≥1 yr ② : ≥5 yrs - <7 yrs	(Footnote 11) To ensure vaccine efficacy, 2 doses are necessary. ①: early vaccination at 1 yr of age ②: simultaneous administration with the 2 nd dose of MR (≥5 yrs - <7 yrs, 1 year before entering elementary school is recommended).	
Japanese Encephalitis	Inactivated	①, ②: 3 yrs, leave a 6-28 days (1-4wks) interval between ①-② ③: 4 yrs, leave a year after ② ④: 9 yrs	JE vaccine is recommended from 6 mos of age in children who will travel or stay in the endemic area of JE, or live in the area where high prevalence of JE antibody in pigs. "Recommendation for JE vaccine from 6 mos of age in children with high risks for JE (in Japanese)". http://www.jpeds.or.jp/modules/activity/index.php?content_id=207	<ul style="list-style-type: none"> · A dose per vaccination: 6mos- <3 yrs: 0.25mL; ≥3 yrs: 0.5mL · For general routine vaccinations, first set administered from 6 mos to under 90 mos (7.5 yrs), and second set at age 9 to under 13 yrs. · Interval of ≥6 days between ①-②, ≥6 mos between ② and ③. · For children who were born from April 2, 1995 to April 1, 2007, it is possible to receive vaccine as a routine vaccine if they did not receive 1st stage (①, ②, ③) during 6 mos-<90 mos (7 yr 6mos) or 9 yrs to <13 yrs. · Due to the assertive recommendation to refrain from administration in May 2005, a detailed schedule for those who were born between April 2, 1995 and October 1, 2007 (in Japanese) . https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryuu/kenkou/kekakaku-kansenshou/yobou-sesshu/vaccine/japanese-encephalitis/index.html

Vaccination Schedule Recommended by the Japan Pediatric Society October 27, 2024

Standard Period, Perspective of the Japan Pediatric Society, Precautions

Routine Vaccination
 Voluntary Vaccination
 By Health Insurance



Vaccine	Type	Standard Age of Vaccination and Period	Perspective of the Japan Pediatrics Society	Precautions
Influenza, Inactivated	Inactivated	Leave an interval of 4 wks between ① and② (2-4 wks)		<ul style="list-style-type: none"> • <13 yrs: 2 doses, ≥13 yrs: 1 or 2 doses (basically 1 dose). • Single dose: 6 mos - <3 yrs: 0.25 mL; ≥3 yrs: 0.5 mL.
Influenza, Intranasal live attenuated	Live	2 yrs -<19 yrs, ① in each influenza season	Live attenuated Influenza vaccine is equally recommended as inactivated Influenza vaccine, except for individuals such as those with asthma, immunocompromised condition. Please refer to "Considerations for the use of intranasal live attenuated influenza vaccine" for details. https://www.jpeds.or.jp/modules/activity/index.php?content_id=607	0.2 mL per dose, intranasally sprayed, 1 dose in every influenza season. (Spray of 0.1 mL in each nostril, a total of two sprays) There is no description to limit the interval between live attenuated influenza vaccine and other vaccine administrations in the vaccine package inserts.
COVID-19	mRNA Inactivated	Vaccination according to the schedule for specified for each formulation.		Refer to "List of COVID-19 vaccines available in Japan" and each vaccine package inserts.
Human Papilloma Virus (HPV)	Inactivated	Junior high school Grade 1 · HPV9 vaccine (SILGARD®9): ① received < 15 yrs, 2 doses recommended, generally leave 6 mos to 12 mos between ①-②. However, if it is not possible to leave this interval, the second dose can be administered if there is an interval of at least 5 mos between ①-②.	If HPV2 or HPV4 was used for the initial vaccination, the same vaccine should be used as a booster. However, HPV9 can also be used as a booster. Male ≥9 yrs can receive 3 doses of HPV4 as a voluntary vaccine.	<ul style="list-style-type: none"> • Vaccine given as intramuscular injection (upper arm, deltoid area) . • By the Immunization Law, 12-16 yrs (elementary school grade 6 to high school year 1) female. • (Footnote 12) HPV2 vaccine can be administered from ≥10 yrs, and HPV4 and 9 vaccine can be administered from ≥9 yrs. • (Footnote 13) Vaccination is possible as routine vaccination with the interval below if not administered in the regular schedule (Note the difference in the interval required for routine vaccination between the 3 vaccines). • HPV9 vaccines (start from ≥15 yrs): ≥1 mo between ①-②, and ≥3 mos between ②-③. • HPV2 vaccine: ≥1 mo between ①-②; ≥5 mos between ①-③ and ≥2.5 mos between ②-③. • HPV4 vaccines: ≥1 mo between ①-②, and ≥3 mos between ②-③. (Footnote 14) If women who were born between 1997 and 2006 (Japanese academic year) and have not received 3 doses of HPV vaccine, because of withholding the recommendation, can receive catch-up vaccinations by March 31 2025. Women born in 2007 (Japanese academic year) can also receive HPV vaccine as a catch-up vaccinations by March 31 2025. For practical vaccination information, please refer to the Ministry of Health, Labor and Welfare website. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou/hpv_catch-up-vaccination.html

Immunization Check List

Name :

Date of Birth : / /

Routine vaccine Voluntary vaccine

Vaccines	Type	Dose 1	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6
Hepatitis B (HBV)	Inactivated	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)			
Rotavirus	Live	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /) <small>Dose 2 final for RV1 (Rotarix®)</small>	<input type="checkbox"/> (/ /) <small>Dose 3 final for RV5 (RotaTeq®)</small>			
Pneumococcal conjugate (PCV15,PCV20)	Inactivated	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /) <small>Refer to Footnote 24</small>	
DPT-IPV-Hib or DPT-IPV or DPT+IPV	Inactivated	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)		
Diphtheria, Pertussis, Tetanus (DPT) (post school age prevention for pertussis)	Inactivated					<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)
Diphtheria, Tetanus (DT)	Inactivated					<input type="checkbox"/> (/ /)	
Polio (post school age prevention for polio)	Inactivated					<input type="checkbox"/> (/ /)	
Haemophilus influenzae type b (Hib)	Inactivated	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)		
BCG	Live	<input type="checkbox"/> (/ /)					
Measles, Rubella (MR)	Live	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)				
Varicella	Live	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)				
Mumps	Live	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)				
Japanese encephalitis	Inactivated	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /)		
Influenza	Inactivated or Live	(Annual vaccination is recommended, please refer to the Influenza Vaccination checklist)					
COVID-19	mRNA or Inactivated	(Annual vaccination is recommended, please refer to the COVID-19 Vaccination checklist)					
Human papillomavirus (HPV)	Inactivated	<input type="checkbox"/> (/ /)	<input type="checkbox"/> (/ /) <small>Two doses are the maximum for those who started the 9-valent vaccine (Silgard®9) under the age of 15.</small>	<input type="checkbox"/> (/ /) <small>The 2-valent vaccine (Cervarix®) and 4-valent vaccine (Gardasil®) require three doses. The 9-valent vaccine (Silgard®9) also requires three doses if started at age 15 or older.</small>			



Influenza Vaccination Checklist

Name : _____

Date of Birth : / /

Age	Dose 1	Dose 2	年齢	Dose 1	Dose 2
6-11 mos	<input type="checkbox"/> Inactivated (/ /)	<input type="checkbox"/> Inactivated (/ /)	8 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	<input type="checkbox"/> Inactivated (/ /)
1 yr	<input type="checkbox"/> Inactivated (/ /)	<input type="checkbox"/> Inactivated (/ /)	9 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	<input type="checkbox"/> Inactivated (/ /)
2 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	<input type="checkbox"/> Inactivated (/ /)	10 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	<input type="checkbox"/> Inactivated (/ /)
3 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	<input type="checkbox"/> Inactivated (/ /)	11 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	<input type="checkbox"/> Inactivated (/ /)
4 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	<input type="checkbox"/> Inactivated (/ /)	12 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	<input type="checkbox"/> Inactivated (/ /)
5 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	<input type="checkbox"/> Inactivated (/ /)	13 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	
6 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	<input type="checkbox"/> Inactivated (/ /)	14 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	
7 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	<input type="checkbox"/> Inactivated (/ /)	15 yrs	<input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /)	

Live attenuated influenza vaccine is administered as a single dose each influenza season.



COVID-19 Vaccination Checklist

Number of doses differs by COVID-19 vaccine products
and the purpose of vaccination.

Name :

Date of Birth : / /

Age				
6-11 mos	Product name	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)	(/ /)
1 yr	Product name	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)	(/ /)
2 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)	(/ /)
3 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)	(/ /)
4 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)	(/ /)
5 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>	
	Date	(/ /)	(/ /)	
6 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>	
	Date	(/ /)	(/ /)	
7 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>	
	Date	(/ /)	(/ /)	

Age			
8 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)
9 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)
10 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)
11 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)
12 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)
13 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)
14 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)
15 yrs	Product name	<input type="checkbox"/>	<input type="checkbox"/>
	Date	(/ /)	(/ /)



List of COVID-19 vaccines available in Japan (as of October 2024)

Manufacturer	Trade Name	Vaccine Antigen (Variants)	Modality	Approved Ages	Dosage	Administration Route	Doses and Intervals between doses
Pfizer Japan Inc.	COMIRNATY for 6 mos to 4 yrs	SARS-CoV-2 Omicron variant JN.1 lineage	mRNA	6 mos - 4 yrs	0.3 mL per dose	Intramuscular	Initial series (no prior SARS-CoV-2 vaccine) : 3 doses (Dose 1 and Dose 2, 3 weeks apart, Dose 3 at least 8 weeks after Dose 2). Booster (any prior SARS-CoV-2 vaccine) : 1 dose at least 3 months after the last SARS-CoV-2 vaccine.
	COMIRNATY for 5 to 11 yrs		mRNA	5 - 11 yrs	0.3 mL per dose	Intramuscular	Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart.
	COMIRNATY for 12 yrs and older		mRNA	12 yrs and older	0.3 mL per dose	Intramuscular	Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart.
Moderna Japan Co. Ltd	SPIKEVAX		mRNA	6 mos - 4 yrs	0.25 mL per dose	Intramuscular	For person with no prior SARS-CoV-2 vaccine: 2 doses typically 4 weeks apart as initial series.
				5 - 11 yrs	0.25 mL per dose	Intramuscular	Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart.
				12 yrs and older	0.5 mL per dose	Intramuscular	Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart.
Daiichi Sankyo Co., Ltd.	DAICHIRONA		mRNA	12 yrs and older	0.6 mL per dose	Intramuscular	Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart.
Takeda Pharmaceutical Co., Ltd.	NUVAXOVID		Recombinant protein	6 - 11 yrs	0.5 mL per dose	Intramuscular	For person with no prior SARS-CoV-2 vaccine: 2 doses typically 3 weeks apart as initial series.
				12 yrs and older	0.5 mL per dose	Intramuscular	Booster: 1 dose <u>at least 6 months</u> after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart.
Meiji Seika Pharma Co., Ltd.	KOSTAIVE	mRNA (replicon)	18 yrs and older	0.5 mL per dose	Intramuscular	Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart.	

